We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venture Life Group Plc | LSE:VLG | London | Ordinary Share | GB00BFPM8908 | ORD 0.3P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.25 | 0.60% | 42.25 | 42.00 | 42.50 | 42.25 | 41.75 | 42.25 | 75,298 | 15:29:20 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Misc Retail Stores, Nec | 43.98M | 520k | 0.0041 | 103.05 | 53.16M |
TIDMVLG
Venture Life Group PLC
16 February 2018
Venture Life Group plc
("Venture Life" or the "Group")
Investor presentation
Venture Life Group (AIM: VLG), the international consumer self-care company focused on developing, manufacturing and commercialising products for the self-care market, is pleased to announce that Jerry Randall, CEO, will be presenting at an investor evening hosted by Turner Pope Investments ("TPI") Ltd.
TPI has been joint broker to Venture Life Group since September 2016. The event will be held on Monday 26 February in the City of London and will commence at 6pm. To Register your interest, please email info@turnerpope.com or call 0203 621 4120.
For further information please contact:
Hot Features
Premium
+44 (0) 1344
Venture Life Group PLC 742870
Jerry Randall, Chief Executive Officer
Turner Pope Investments (TPI) Ltd +44 (0) 20 3621
(Joint Broker) 4120
Rachel Evans
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising self-care products globally. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.
The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its Development & Manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAPASFAEPEFF
(END) Dow Jones Newswires
February 16, 2018 02:00 ET (07:00 GMT)
1 Year Venture Life Chart |
1 Month Venture Life Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
